Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Investor Presentation (March 2023)
23 slides from Staar Surgical's investor presentation, Mar 14, 2023
Slide 1: Envision a Life Without Hesitation
Envision a Life Without Hesitation STAAR Surgical Investor Presentation NASDAQ: STAA | March 2023 Exhibit 99.1
Slide 2: Forward Looking Statements
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023 or prospects for achieving such plans, expectations for sal
Slide 3: Upgrade Your Vision
UPGRADE YOUR VISION 99% patient satisfaction* Become the standard of care for refractive vision correction, gaining broad-based surgeon acceptance of our family of EVO Implantable Collamer® Lenses (ICLs) as a primary procedure, and freeing patients from the hassles of glasses and contact lenses. Con
Slide 4: Why Invest in STAAR Surgical?
04 Why Invest in STAAR Surgical? Multi-Year track record of 25%+ Y/Y sales growth Multi-Year track record of GAAP profitability Large and growing addressable market Wide competitive moat and negligible lens-based competition Gaining share and adding procedures to markets where we invest With 2022 EV
Slide 5: Sustainability
05 Sustainability Elevated ESG stewardship to a strategic imperative Cross-functional team advancing our ESG goals Several projects completed or underway designed to reduce energy, waste and water Initial analysis of solar photovoltaic panel initiative indicates STAAR will reduce energy demand from
Slide 6: EVO ICL Technology
06 EVO ICL Technology Natural Crystalline Lens EVO ICL™ Iris A single-piece foldable phakic intraocular lens (IOL) implanted within the posterior chamber of the eye, directly behind the iris and in front of the natural crystalline lens, designed to correct/reduce refractive error (blurred vision), e
Slide 7: ICL Unit Growth Exceeds Refractive Industry Procedure Growth
07 2019 2020 2021 2022 Global Refractive Industry Procedures* Global ICL Units * Market Scope, January 2019-2023. STAAR’s ICL Unit Growth Significantly Exceeds Refractive Industry Procedure Growth Year-Over-Year Growth
Slide 8: STAAR's Sales Growth Significantly Exceeds Ophthalmic Peers
08 STAAR’s Sales Growth Significantly Exceeds Ophthalmic Peers, Market Scope OMP Monthly* Financial Excellence STAAR Q1-2022 Net Sales Up 25% Y/Y STAAR Q2-2022 Net Sales Up 30% Y/Y STAAR Q3-2022 Net Sales Up 30% Y/Y Change in Revenue in Q1-2022 vs. Q1-2021* Horizon Therapeutics Aerie Pharmaceuticals
Slide 9: Consistent 25%+ ICL Sales Growth Y/Y
2019 2020 2021 2022 2023 Outlook +28% Growth $129.3 M 2019 +51% Growth $212.9 M 2021 +27% Growth $269.7 M 2022 +9% Growth $141.4 M* 2020 +26% Growth $340.0 M** 2023P Initial COVID-19 Impact 09 Consistent 25%+ ICL Sales Growth Y/Y Financial Excellence * Initial sales outlook provided prior to COVID o
Slide 10: Drives Margins, EPS and Cash
10 Drives Margins, EPS and Cash Financial Excellence | Units, Sales and Prudent Investment * 2019 Includes $0.07 GILTI tax benefit. Cash on Balance Sheet $ Millions Gross Margin GAAP EPS * Cash from Operations $ Millions at Year End Operating Margin
Slide 11: Large Addressable Market Opportunity: Myopia
Large Adressable Market Opportunity Myopia | The Need for Distance Vision Correction 11 * BHVI, adapted from Holden et al. 2016 Ophthalmology. ** Market Scope, 2022 Refractive Error Model. Prevalence, Global Myopia* Diopter Distribution, Global Myopia ** (Millions of People) 2 Billion+ Myopes 3x 5x
Slide 12: 4.3M Annual Global Refractive Procedures
12 4.3 M ~ 12% Annual Global EVO ICL share of Annual Global Refractive Procedures EVO Market Share EVO Market Share EVO Approved November 2022 1,200,000 Annual Procedure Market 850,000 Annual Procedure Market 450,000 125,000 100,000 100,000 250,000 200,000 Refractive Procedures* 4.3 Million Annual G
Slide 13: Why EVO ICL?
13 Patients and Surgeons Tell Us… Why EVO ICL? Excellent Vision Day & Night Additive Bio-Compatible No Capital Equipment Investment Upgradeable Happy Patients Quiet in the Eye Collamer Material No Dry Eye Syndrome UV Protection Removable by a Doctor
Slide 14: Growth Investment
Growth Investment EVO Influencer Programs Instagram Facebook TikTok EVO Brand Display Search Engine Advertising Advertising (SEM) TikTok Snapchat Connected TV Note: Approved age range for EVO family of myopia lenses is generally from age 21 to age 60, and in the US. toage 45, STAARSURGICAL Results @
Slide 15: Growth Investment
Growth Investment STAARSURGICAL Click for Global Consumer
Slide 16: STAAR, A Global Company
16 Direct Hybrid Distributor United States Canada U.K. Germany Spain Japan Singapore China S. Korea India France Benelux Italy STAAR, A Global Company EVO Lenses Sold in 75+ Countries Note: Not all distributor markets shown above, e.g., South America and Africa.
Slide 17: China
China © China: EVO ICL approved in 2015; implemented STAAR’s model of strategic cooperation in January 2016 i In-person and virtual patient roadshows and clinic training on socia! media such as WeChat, integral to demand cycle “D STAARSURGICAL Click for Surgeon Testimonial Video WHICH FACTOR MAKES Y
Slide 18: United States
18 United States U.S. Refractive Procedures in 4Q 2022 Y/Y* U.S. EVO ICL Units in 4Q 2022 Y/Y -15% +109% Calendar 2022 U.S. Refractive Procedures* Opportunity Build the U.S. Refractive Procedures Market** 850K 2.2M+ * Market Scope. ** 1.4 million U.S. refractive procedures in 2008 growing at 3% CAGR
Slide 19: United States: 2023 Focus
19 United States Drive U.S. growth, where STAAR currently has <2% share, by successfully commercializing our EVO ICL family of myopia lenses following FDA Approval on March 25, 2022. Partner more closely with trained surgeons to increase each clinic’s mix of EVO procedures. Fiscal 2023 Outlook is fo
Slide 20: Recent Quarterly Results
20 Recent Quarterly Results Reported February 21, 2023 Fourth Quarter 2022 Fourth Quarter 2022 21% 20% 15% Highlights Constant Currency ICL Sales Growth Y/Y to $64.3 Million Global ICL Unit Growth Y/Y ICL Sales Growth Y/Y to $61.2 Million Y/Y ICL sales growth led by APAC and NA regions while EMEA sa
Slide 21: Financial Excellence is a Core Competency
21 Financial Excellence is a Core Competency Income Statement and Fiscal 2023 Outlook Outlook 2023 1Q23 ICL Sales of $65 million to $67 million, representing 11% to 14% growth over $58.7 million year ago Growth investments to drive surgeon engagement and consumer awareness Net Sales outlook for ~ $3
Slide 22: Upcoming Investor Events
22 Upcoming Investor Events Barclays Healthcare Conference Miami, FL STAAR 1Q23 Earnings Report Mizuho Non-Deal Roadshow New York, NY Jefferies Investor Lunch @ ASCRS 2023 San Diego, CA Barclays Investor Bus Tour Lake Forest, CA William Blair Growth Conference Chicago, IL Benchmark Virtual Healthcar
Slide 23: Envision a Life Without Hesitation
Envision a Life Without Hesitation NASDAQ: STAA www.staar.com www.evoicl.com